



## NEWS RELEASE

### BIOSENSORS ANNOUNCES STRATEGIC AGREEMENT WITH CARDINAL HEALTH

**Singapore, 12 May 2016** – Biosensors International Group, Ltd. (“**Biosensors**” or the “**Company**”), a developer, manufacturer and marketer of innovative medical devices, today announced that it has entered into a strategic distribution agreement with Cardinal Health.

Through this distribution agreement, Biosensors will significantly increase the market coverage and penetration of its leading family of Drug Eluting Stents (DES) which include the innovative BioFreedom™ polymer-free drug coated stent (DCS) clinically proven to be effective in the treatment of High Bleeding Risk (HBR) patients; the market-proven BioMatrix NeoFlex™ and the recently introduced BioMatrix Alpha™, a cobalt chromium DES with an abluminal bio-absorbable coating and the proprietary BA-9 Biolimus™ drug; and Chroma™, a cobalt-chromium bare metal stent (BMS).

The agreement will initially enable Cordis, Cardinal Health’s interventional vascular business, to sell Biosensors family of DES in various European countries, Australia and New Zealand. Over time, Biosensors and Cardinal Health will partner to further leverage their respective distribution capabilities in select regions.

“The agreement between Biosensors and Cardinal Health is an important milestone in our continuing strategy to deepen our market penetration and expand as well as diversify our product offering”, said Jose (Pepe) Calle, Group CEO of Biosensors. “By working together we will be able to leverage our joint capabilities in delivering world-class breakthrough products including BioFreedom™, as well as maximizing the increased market coverage and geographical footprint of the Biosensors and Cordis franchises.”

Last year, Biosensors announced the exciting results of the LEADERS FREE clinical trial which confirmed the safety and efficacy of BioFreedom™ in one of the largest ever double-blind, randomized, clinical trials involving a DES. The data, which were published in the *New England Journal of Medicine* as the world’s first prospective, double-blind, randomized clinical trial focusing on patients at high bleeding risk, demonstrated superior safety and efficacy for BioFreedom™ as compared to an uncoated BMS in patients who could tolerate only one month of dual anti-platelet therapy (DAPT)<sup>3</sup>. The LEADERS FREE trial included 2,466 patients across 68 sites in 20 countries in Europe, Asia, Australia and Canada and used the shortest course of DAPT ever used with an active stent.

“I am excited about the potential of the partnership,” said Mr. Calle. “With our superior technologies, strong relationships with Physicians and Medical Practitioners as well as our positive partnership with the Healthcare community around the world I am confident that Biosensors is continuing to strengthen its position in the global cardiovascular care market.”

###

**Main Contact**

David Chin

Tel: (65) 6213 5777

Email: [ir@biosensors.com](mailto:ir@biosensors.com)

**About Biosensors International Group, Ltd**

Biosensors International Group, Ltd. develops, manufactures and markets innovative medical devices, aiming to improve patients’ lives through pioneering medical technology that pushes forward the boundaries of innovation. Founded in 1990, we are a privately held company.

The Group currently operates through three business units (“BU”): the Cardiovascular BU, composed primarily of the BioMatrix™ family of drug-eluting stents, the BioFreedom™ polymer-free drug coated stent and stent technologies such as BA9; the Cardiac Diagnostic BU, including Spectrum Dynamics products that offer advanced medical imaging and clinical solutions to help interventional cardiologists determine the most appropriate treatment for patients; and the Critical Care Products BU.

The Group has operations worldwide and is headquartered in Singapore.

For more information, please visit [www.biosensors.com](http://www.biosensors.com).